PNOC020 rMBNCT07492316
RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrollment reopened
- Study sites: 1 to 2
- Notable Eligibility criteria expanded, about 36 words
- Enrollment closed, study ongoing
- Site details revised
- Minor Start date changed from estimate of May 15, 2026 to Apr 24, 2026v3
- Notable Recruitment opened
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Manufacturing feasibility
Timeframe: from the date of surgery until administration of third vaccine, up to 15 weeks
Safety of RNA-LP vaccine
Timeframe: First vaccine through 14 days after administration of the 3rd vaccine
Determination of Maximum Tolerated Dose
Timeframe: up to 60 months
Arms and interventions
recurrent/progressive Medulloblastoma (rMB)Experimental
Biologicals: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Sites
2 sites in 1 country